Checkpoint inhibitors have done wonders for immuno-oncology, but the potent class of drugs doesn’t work across all cancers. To remedy this, UK-based biotech upstart Grey Wolf Therapeutics is working on a fresh approach that does not directly target the immune system, but instead alters tumor cells by illuminating and priming them for immune system annihilation — a strategy that could work in conjunction with existing immunotherapies.
Andera Partners and Canaan have shown their faith in the concept by leading an approximately $14 million series A round for the company.
Peter Joyce
Founded by former Vertex executive Peter Joyce and ex-chief of Spinifex Pharmaceuticals Tom McCarthy, Grey Wolf is developing small molecule
